Role of presepsin in predicting sepsis and mortality in COVID-19 pneumonia

Yıl 2023, Cilt: 15 Sayı: 3, 95 - 100, 31.12.2023

Veysi Siber Hatice Kübra Siber Murat Aysin Sertaç Güler Özlem Özbaş Demirel Dursun Bugra Dereyurt Sümeyye Alkan Yavuz Otal Yahya Kemal Günaydın Mehmet Okumuş

https://doi.org/10.35514/mtd.2024.100

Öz

ABSTRACT
Introduction/Background: We aimed to investigate the prognostic significance of Presepsin(PSP) in the patients with Coronavirus Disease 2019 pneumonia who admitted to the emergency department.
Material and Method: This study was conducted as a prospective, case-controlled, observational study. 123 patients with a diagnosis of COVID-19 pneumonia were chosen for the case group and 123 volunteers were enrolled as a control group. 62 of the patients were classified into the sepsis group and 61 patients were placed into the non-sepsis group. The follow-up and treatment of the patients were carried out according to the COVID-19 Severe Pneumonia, ARDS, Sepsis, and Septic Shock Management Guideline of the Turkiye Ministry of Health. The PSP level was studied in patients with and without sepsis diagnosed with COVID-19 pneumonia.
Results: There was no statistically significant difference between the control group, the sepsis group, and the non-sepsis group when the PSP values were compared. However, when the ROC curve was studied for the case group, a statistically significant difference between the survivors and non-survivors was discovered (p<0.05).
Conclusion: No statistically significant distinction in PSP values between the control group and the septic and non-septic patient groups with COVID-19 pneumonia was found. However, PSP values were shown to be statistically significant in mortality of COVID-19 pneumonia and survival.
Keywords: COVID-19, Emergency Medicine, Human Presepsin Protein, Pneumonia, Sepsis

Anahtar Kelimeler

COVID-19, Emergency Medicine, Human Presepsin Protein, Pneumonia, Sepsis

Presepsinin COVID-19 pnömonisinde sepsis ve mortaliteyi öngörmedeki rolü

Öz

ÖZET
Giriş/Arka Plan: Bu çalışmada, acil servise başvuran Coronavirus Disease 2019 pnömonisi olan hastalarda Presepsin (PSP) in prognostik önemini araştırmayı amaçladık.
Materyal ve Metot: Bu çalışma, prospektif, vaka-kontrollü, gözlemsel bir çalışma olarak yapılmıştır. COVID-19 pnömonisi tanısı konulan 123 hasta vaka grubu olarak seçilmiş ve 123 gönüllü de kontrol grubu olarak dahil edilmiştir. Hastaların 62'si sepsis grubuna, 61'i ise sepsis olamayan grup olarak sınıflandırılmıştır. Hastaların takibi ve tedavisi, Türkiye Sağlık Bakanlığı COVID-19 Ciddi Pnömoni, ARDS, Sepsis ve Septik Şok Yönetim Kılavuzu'na göre yapılmıştır. PSP düzeyi, COVID-19 pnömonisi tanısı konulan hastalarda sepsisli ve sepsisli olmayanlar arasında incelenmiştir.
Sonuçlar: PSP değerleri karşılaştırıldığında, kontrol grubu, sepsis grubu ve sepsis olamayan grup arasında istatistiksel olarak anlamlı farklılık bulunmamıştır. Ancak vaka grubu için ROC eğrisi incelendiğinde, sağ kalanlar ve sağ kalmayanlar arasında istatistiksel olarak anlamlı fark saptanmıştır (p<0.05).
Sonuç: COVID-19 pnömonisi olan hastalarda kontrol grubu ile sepsis ve sepsis olmayan hasta grupları arasında PSP değerleri arasında istatistiksel olarak anlamlı fark bulunmamıştır. Ancak PSP değerleri, COVID-19 pnömonisi mortalitesi ve sağ kalımında istatistiksel olarak anlamlı bulunmuştur.
Anahtar kelimeler: Acil Tıp, COVID-19, Human Presepsin Protein, Sepsis, Pnömoni

Anahtar Kelimeler

Acil Tıp, COVID-19, Human Presepsin Protein, Sepsis, Pnömoni

Kaynakça

• Ahmed S, Jafri L, Majid H, Khan AH, Ghani F, Siddiqui I. Challenges amid Covid-19 times - Review of the changing practices in a clinical chemistry laboratory from a developing country. Annals of medicine and surgery. 2020;55:300-304.
• Chenevier-Gobeaux C, Borderie D, Weiss N, Mallet-Coste T, Claessens YE. Presepsin (sCD14-ST), an innate immune response marker in sepsis. Clinica chimica acta; international journal of clinical chemistry. 2015;450:97-103.
• Memar MY, Baghi HB. Presepsin: A promising biomarker for the detection of bacterial infections. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019;111:649-656.
• Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2011;17(6):764-769.
• Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clinica chimica acta; international journal of clinical chemistry. 2011;412(23-24):2157-2161.
• Fukada A, Kitagawa Y, Matsuoka M, Sakai J, Imai K, Tarumoto N, et al. Presepsin as a predictive biomarker of severity in Covid-19: A case series. Journal of medical virology. 2021;93(1):99-101.
• Dell'Aquila P, Raimondo P, Orso D, De Luca P, Pozzessere P, Parisi CV, et al. A simple prognostic score based on troponin and presepsin for Covid-19 patients admitted to the emergency department: a single-center pilot study. Acta bio-medica : Atenei Parmensis. 2021;92(4):e2021233.
• Zaninotto M, Mion MM, Cosma C, Rinaldi D, Plebani M. Presepsin in risk stratification of SARS-CoV-2 patients. Clinica chimica acta; international journal of clinical chemistry. 2020;507:161-163.
• Ahmed S, Mansoor M, Shaikh MS, Siddiqui IJIJoCCMP-r, Official Publication of Indian Society of Critical Care Medicine. Presepsin as a Predictive Biomarker of Severity in Covid-19: A Systematic Review. 2021;25(9):1051.
• Bertsimas D, Lukin G, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B, et al. Covid-19 mortality risk assessment: An international multi-center study. PloS one. 2020;15(12):e0243262.
• Rechtman E, Curtin P, Navarro E, Nirenberg S, Horton MKJSr. Vital signs assessed in initial clinical encounters predict Covid-19 mortality in an NYC hospital system. 2020;10(1):1-6.
• Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors Associated With Mortality Among Patients With Covid-19 in Intensive Care Units in Lombardy, Italy. JAMA internal medicine. 2020;180(10):1345-1355.
• Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (Covid-19) infection: a systematic review and meta-analysis of observational studies. The aging male: the official journal of the International Society for the Study of the Aging Male. 2020;23(5):1416-1424.
• Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with Covid-19. American journal of respiratory and critical care medicine. 2020;201(11):1430-1434.
• Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (Covid-19): a meta-analysis. Clinical chemistry and laboratory medicine. 2020;58(7):1021-1028.
• Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with Covid-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054-1062.
• Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with Covid-19: A systematic review. PloS one. 2020;15(11):e0241955.
• Káňová M, Dobiáš R, Liszková K, Frelich M, Ječmínková R, Kula R. Presepsin in the diagnostics of sepsis. Vnitrni lekarstvi. 2019;65(7-8):497-505.